According to filings with the U.S. Securities and Exchange Commission, Mirvie is raising up to $29,999,973.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Mirvie
Mirvie is the 1st to predict pregnancy complications before they happen by using RNA messages to reveal underlying biology of pregnancy health. Using a simple blood test, the platform reveals vital information about a pregnancys unique biology that drives changes throughout pregnancy. The result? The power to transform how we predict, prevent and treat unexpected complications. .

To learn more about Mirvie, visit https://www.mirvie.com/
Mirvie Linkedin Page: https://www.linkedin.com/company/mirvie/

Contact:
Maneesh Jain, Chief Executive Officer
650-741-6510
https://www.linkedin.com/in/maneesh-jain-2509388/

SOURCE: http://www.intelligence360.io
Copyright (c) 2025 SI360 Inc. All rights reserved.